Skip to main content

Table 3 Comparison of clinical features between the groups according to one year virologic response

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Variables Patients with VR
(n = 161)
Patients without VR
(n = 49)
P
Age (years) 46.8 ± 11.0 44.4 ± 14.7 0.285
Sex (male, %) 99 (61.5) 32 (65.3) 0.737
HBeAg-positive (%) 77 (47.8) 44 (89.8) <0.001
Disease status;
CHB/LC (%)
85/76
(52.8/47.2)
41/8
(83.7/16.3)
<0.001
MELD (<7/7-13/>13, %) 109/47/5
(67.7/29.2/3.1)
35/12/2
(71.4/24.5/4.1)
0.768
Serum ALT (IU/L) 198.0 ± 305.7 231.8 ± 475.0 0.557
Serum total bilirubin (mg/dL) 1.12 ± 1.46 1.19 ± 1.77 0.774
Serum albumin(g/dL) 4.10 ± 0.53 4.11 ± 0.60 0.952
INR 1.12 ± 0.17 1.09 ± 0.21 0.319
IVR-3 (−/+) 12/149(7.5/92.5) 25/24 (51.0/49.0) <0.001
Serum HBV DNA level (log10 IU/mL) 6.30 ± 1.23 7.61 ± 0.97 <0.001
Treatment regimens    0.192
 ETV (n = 105, %) 76 (72.4) 29 (27.6)  
 TDF (n = 105, %) 85 (81.0) 20 (19.0)  
  1. Data are expressed as mean ± standard deviation or number
  2. ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio, IVR-3 initial virologic response at 3 months, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir, VR virologic response